| BMI <30 kg/m2 | BMI ≥30 kg/m2 | |||
|---|---|---|---|---|
| Continuous Use Celecoxib 200 mg qd n=209 n (%) | Intermittent Use Celecoxib 200 mg qd n=205 n (%) | Continuous Use Celecoxib 200 mg qd n=222 n (%) | Intermittent Use Celecoxib 200 mg qd n=222 n (%) | |
| Total no. patients with AE | 114 (54.5) | 121 (59.0) | 131 (59.0) | 130 (58.6) |
| AE ≥2% Patients in Either Treatment Group by Preferred Term | ||||
| Headache | 33 (15.8) | 32 (15.6) | 32 (14.4) | 36 (16.2) |
| Back pain | 10 (4.8) | 20 (9.8) | 10 (4.5) | 11 (5.0) |
| Arthralgia | 9 (4.3) | 14 (6.8) | 8 (3.6) | 11 (5.0) |
| Nasopharyngitis | 7 (3.3) | 8 (3.9) | 12 (5.4) | 12 (5.4) |
| Diarrhea | 1 (0.5) | 11 (5.4) | 6 (2.7) | 6 (2.7) |
| Pain in extremity | 9 (4.3) | 10 (4.9) | 9 (4.1) | 11 (5.0) |
| Dyspepsia | 6 (2.9) | 3 (1.5) | 11 (5.0) | 3 (1.4) |
| Upper respiratory tract infection | 7 (3.3) | 9 (4.4) | 7 (3.2) | 10 (4.5) |
| Hypertension | 2 (1.0) | 9 (4.4) | 7 (3.2) | 4 (1.8) |
| Upper abdominal pain | 3 (1.4) | 9 (4.4) | 4 (1.8) | 1 (0.5) |
| Sinusitis | 5 (2.4) | 1 (0.5) | 6 (2.7) | 9 (4.1) |
| Musculoskeletal pain | 4 (1.9) | 3 (1.5) | 3 (1.4) | 9 (4.1) |
| Insomnia | 3 (1.4) | 6 (2.9) | 8 (3.6) | 2 (0.9) |
| Edema peripheral | 3 (1.4) | 5 (2.4) | 1 (0.5) | 7 (3.2) |
| Bronchitis | 2 (1.0) | 2 (1.0) | 1 (0.5) | 7 (3.2) |
| Muscle spasms | 7 (3.3) | 1 (0.5) | 3 (1.4) | 4 (1.8) |
| Dizziness | 6 (2.9) | 6 (2.9) | 2 (0.9) | 2 (0.9) |
| Nausea | 2 (1.0) | 6 (2.9) | 3 (1.4) | 3 (1.4) |
| Abdominal pain | 4 (1.9) | 2 (1.0) | 6 (2.7) | 2 (0.9) |
| Contusion | 1 (0.5) | 1 (0.5) | 2 (0.9) | 6 (2.7) |
| Myalgia | 4 (1.9) | 4 (2.0) | 6 (2.7) | 5 (2.3) |
| Toothache | 1 (0.5) | 4 (2.0) | 2 (0.9) | 2 (0.9) |
| Fatigue | 0 (0) | 6 (2.9) | 6 (2.7) | 3 (1.4) |
| Pain | 4 (1.9) | 6 (2.9) | 2 (0.9) | 3 (1.4) |
| Influenza | 5 (2.4) | 4 (2.0) | 5 (2.3) | 5 (2.3) |
| Vomiting | 1 (0.5) | 4 (2.0) | 4 (1.8) | 2 (0.9) |
| Viral infection | 0 (0) | 4 (2.0) | 3 (1.4) | 0 (0) |
| Rash | 0 (0) | 4 (2.0) | 1 (0.5) | 3 (1.4) |